Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 23 (9), 1133-1144, 2022-09
Elsevier BV